DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/mtnt73/global_ankylosing) has announced the addition of the "Global Ankylosing Spondylitis Market 2015-2019" report to their offering.
Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely.
It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature.
The dominance of the market by biologics for the treatment of patients suffering from ankylosing spondylitis is one key trend in the market. Biologics are expected to be a preferred treatment option among the medical fraternity, patients, and the families of patients during the forecast period. This increases the number of treatment-seeking patients, which increases the overall consumption of medicines.
According to the report, presence of high unmet needs in terms of appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely, and the drugs have a low safety profile, resulting in a rate high mortality. Therefore, drugs that can cause disease remission in patients and have a high safety profile are expected to drive the growth of the market.
Further, the report states that expiry of patents is one of the major challenges hindering the growth of the market. Loss of patents of major drugs used in treatment of ankylosing spondylitis is expected to lower their revenue share, leading to a decrease in the overall revenue of the vendors in the market.
The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below:
- TNF Inhibitors
- COX Inhibitors
On the type of molecule used for the treatment of ankylosing spondylitis, as illustrated below:
- Small Molecules
On the basis of route of administration adopted for the treatment of ankylosing spondylitis, the Global Ankylosing Spondylitis market is segmented as follows:
In addition, the market is also bifurcated on the basis of dosage forms of the drugs used in the treatment of the disease:
- Janssen Pharmaceuticals
- Merck & Co.
For more information visit http://www.researchandmarkets.com/research/mtnt73/global_ankylosing